{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:01:38Z","timestamp":1794304898965,"version":"4.9.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI129698"],"award-info":[{"award-number":["AI129698"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI140844"],"award-info":[{"award-number":["AI140844"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ebola virus (EBOV) glycoprotein (GP) can be recognized by neutralizing antibodies (NAbs) and is the main target for vaccine design. Here, we first investigate the contribution of the stalk and heptad repeat 1-C (HR1\n                    <jats:sub>C<\/jats:sub>\n                    ) regions to GP metastability. Specific stalk and HR1\n                    <jats:sub>C<\/jats:sub>\n                    modifications in a mucin-deleted form (GP\u0394muc) increase trimer yield, whereas alterations of HR1\n                    <jats:sub>C<\/jats:sub>\n                    exert a more complex effect on thermostability. Crystal structures are determined to validate two rationally designed GP\u0394muc trimers in their unliganded state. We then display a modified GP\u0394muc trimer on reengineered protein\u00a0nanoparticles that encapsulate a layer of locking domains (LD) and a cluster of helper T-cell epitopes. In mice and rabbits, GP trimers and nanoparticles elicit cross-ebolavirus NAbs, as well as non-NAbs that enhance pseudovirus infection. Repertoire sequencing reveals quantitative profiles of vaccine-induced B-cell responses. This study demonstrates a promising vaccine strategy for filoviruses, such as EBOV, based on GP stabilization and nanoparticle display.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-22867-w","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T06:04:54Z","timestamp":1620713094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines"],"prefix":"10.1038","volume":"12","author":[{"given":"Linling","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Sou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanwee","family":"Alkutkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-2880","authenticated-orcid":false,"given":"Sonu","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Kosviner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-8138","authenticated-orcid":false,"given":"Gabriel","family":"Ozorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-3769","authenticated-orcid":false,"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-2419","authenticated-orcid":false,"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-7157","authenticated-orcid":false,"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"22867_CR1","first-page":"1229","volume":"159","author":"JH Kuhn","year":"2014","unstructured":"Kuhn, J. H. et al. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch. Virol. 159, 1229\u20131237 (2014).","journal-title":"Arch. Virol."},{"key":"22867_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","volume":"8","author":"S Paessler","year":"2013","unstructured":"Paessler, S. & Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 8, 411\u2013440 (2013).","journal-title":"Annu. Rev. Pathol."},{"key":"22867_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","volume":"393","author":"D Malvy","year":"2019","unstructured":"Malvy, D., McElroy, A. K., de Clerck, H., Gunther, S. & van Griensven, J. Ebola virus disease. Lancet 393, 936\u2013948 (2019).","journal-title":"Lancet"},{"key":"22867_CR4","unstructured":"Ebola outbreak 2014-2016 (https:\/\/www.who.int\/csr\/disease\/ebola\/en\/)."},{"key":"22867_CR5","unstructured":"Ebola situation reports: Democratic Republic of the Congo (https:\/\/www.who.int\/ebola\/situation-reports\/drc-2018\/en\/)."},{"key":"22867_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.coph.2016.08.016","volume":"30","author":"AP Cardile","year":"2016","unstructured":"Cardile, A. P., Downey, L. G., Wiseman, P. D., Warren, T. K. & Bavari, S. Antiviral therapeutics for the treatment of Ebola virus infection. Curr. Opin. Pharmacol. 30, 138\u2013143 (2016).","journal-title":"Curr. Opin. Pharmacol."},{"key":"22867_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-pharmtox-010716-105055","volume":"57","author":"AP Cardile","year":"2017","unstructured":"Cardile, A. P., Warren, T. K., Martins, K. A., Reisler, R. B. & Bavari, S. Will there be a cure for Ebola? Annu. Rev. Pharmacol. Toxicol. 57, 329\u2013348 (2017).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"22867_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molmed.2017.06.008","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. & Geisbert, T. W. Neutralizing the threat: pan-ebolavirus antibodies close the loop. Trends Mol. Med. 23, 669\u2013671 (2017).","journal-title":"Trends Mol. Med."},{"key":"22867_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.coviro.2019.01.003","volume":"34","author":"LB King","year":"2019","unstructured":"King, L. B., Milligan, J. C., West, B. R., Schendel, S. L. & Saphire, E. O. Achieving cross-reactivity with pan-ebolavirus antibodies. Curr. Opin. Virol. 34, 140\u2013148 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"22867_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"XG Qiu","year":"2014","unstructured":"Qiu, X. G. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"22867_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"RT Davey","year":"2016","unstructured":"Davey, R. T. et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375, 1448\u20131456 (2016).","journal-title":"N. Engl. J. Med."},{"key":"22867_CR12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"22867_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","volume":"393","author":"MR Gaudinski","year":"2019","unstructured":"Gaudinski, M. R. et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 393, 889\u2013898 (2019).","journal-title":"Lancet"},{"key":"22867_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","volume":"389","author":"FC Zhu","year":"2017","unstructured":"Zhu, F. C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621\u2013628 (2017).","journal-title":"Lancet"},{"key":"22867_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","volume":"377","author":"SB Kennedy","year":"2017","unstructured":"Kennedy, S. B. et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in liberia. N. Engl. J. Med. 377, 1438\u20131447 (2017).","journal-title":"N. Engl. J. Med."},{"key":"22867_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"22867_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/infdis\/jiu511","volume":"211","author":"UN Sarwar","year":"2015","unstructured":"Sarwar, U. N. et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase I clinical trial. J. Infect. Dis. 211, 549\u2013557 (2015).","journal-title":"J. Infect. Dis."},{"key":"22867_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"22867_CR19","doi-asserted-by":"publisher","first-page":"e5547","DOI":"10.1371\/journal.pone.0005547","volume":"4","author":"XG Qiu","year":"2009","unstructured":"Qiu, X. G. et al. Mucosal immunization of cynomolgus macaques with the VSV delta G\/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One 4, e5547 (2009).","journal-title":"PLoS One"},{"key":"22867_CR20","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1128\/JVI.00561-09","volume":"83","author":"TW Geisbert","year":"2009","unstructured":"Geisbert, T. W. et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 83, 7296\u20137304 (2009).","journal-title":"J. Virol."},{"key":"22867_CR21","doi-asserted-by":"publisher","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","volume":"4","author":"TW Geisbert","year":"2008","unstructured":"Geisbert, T. W. et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 4, e1000225 (2008).","journal-title":"PLoS Pathog."},{"key":"22867_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0140-6736(18)31710-0","volume":"392","author":"Y L\u00e9vy","year":"2018","unstructured":"L\u00e9vy, Y. et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet 392, 787\u2013790 (2018).","journal-title":"Lancet"},{"key":"22867_CR23","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","volume":"110","author":"A Marzi","year":"2013","unstructured":"Marzi, A. et al. Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893\u20131898 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22867_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.celrep.2019.01.069","volume":"26","author":"IL McWilliams","year":"2019","unstructured":"McWilliams, I. L. et al. Pseudovirus rVSV delta G-ZEBOV-GP infects neurons in retina and CNS, causing apoptosis and neurodegeneration in neonatal mice. Cell Rep. 26, 1718\u20131726.e1714 (2019).","journal-title":"Cell Rep."},{"key":"22867_CR25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.celrep.2018.07.035","volume":"24","author":"NA Kuzmina","year":"2018","unstructured":"Kuzmina, N. A. et al. Antibody-dependent enhancement of Ebola virus infection by human antibodies isolated from survivors. Cell Rep. 24, 1802\u20131815.e1805 (2018).","journal-title":"Cell Rep."},{"key":"22867_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/fvl.09.56","volume":"4","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621\u2013635 (2009).","journal-title":"Future Virol."},{"key":"22867_CR27","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1073\/pnas.1502619112","volume":"112","author":"AK McElroy","year":"2015","unstructured":"McElroy, A. K. et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl Acad. Sci. USA 112, 4719\u20134724 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22867_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2019.04.036","volume":"177","author":"CW Davis","year":"2019","unstructured":"Davis, C. W. et al. Longitudinal analysis of the human B cell response to Ebola virus infection. Cell 177, 1566\u20131582.e1517 (2019).","journal-title":"Cell"},{"key":"22867_CR29","doi-asserted-by":"publisher","first-page":"e01439","DOI":"10.1128\/JVI.01439-18","volume":"93","author":"LE Williamson","year":"2019","unstructured":"Williamson, L. E. et al. Early human B cell response to Ebola virus in four US survivors of infection. J. Virol. 93, e01439\u201301418 (2019).","journal-title":"J. Virol."},{"key":"22867_CR30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.tim.2016.05.008","volume":"24","author":"EO Saphire","year":"2016","unstructured":"Saphire, E. O. & Aman, M. J. Feverish quest for Ebola immunotherapy: straight or cocktail? Trends Microbiol. 24, 684\u2013686 (2016).","journal-title":"Trends Microbiol."},{"key":"22867_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"22867_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","volume":"23","author":"LB King","year":"2018","unstructured":"King, L. B. et al. The marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23, 101\u2013109.e104 (2018).","journal-title":"Cell Host Microbe"},{"key":"22867_CR33","doi-asserted-by":"publisher","first-page":"e1005016","DOI":"10.1371\/journal.ppat.1005016","volume":"11","author":"ML Fusco","year":"2015","unstructured":"Fusco, M. L. et al. Protective mAbs and cross-reactive mAbs raised by immunization with engineered Marburg virus GPs. PLoS Pathog. 11, e1005016 (2015).","journal-title":"PLoS Pathog."},{"key":"22867_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/JVI.02172-15","volume":"90","author":"ZY Keck","year":"2016","unstructured":"Keck, Z. Y. et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J. Virol. 90, 279\u2013291 (2016).","journal-title":"J. Virol."},{"key":"22867_CR35","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","volume":"15","author":"KA Howell","year":"2016","unstructured":"Howell, K. A. et al. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep. 15, 1514\u20131526 (2016).","journal-title":"Cell Rep."},{"key":"22867_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","volume":"169","author":"XL Zhao","year":"2017","unstructured":"Zhao, X. L. et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169, 891\u2013904.e815 (2017).","journal-title":"Cell"},{"key":"22867_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.aad5788","volume":"351","author":"ZA Bornholdt","year":"2016","unstructured":"Bornholdt, Z. A. et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078\u20131083 (2016).","journal-title":"Science"},{"key":"22867_CR38","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","volume":"169","author":"AZ Wec","year":"2017","unstructured":"Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878\u2013890 (2017).","journal-title":"Cell"},{"key":"22867_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","volume":"49","author":"P Gilchuk","year":"2018","unstructured":"Gilchuk, P. et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein. Immunity 49, 363\u2013374.e310 (2018).","journal-title":"Immunity"},{"key":"22867_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"22867_CR41","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nsmb.2150","volume":"18","author":"JM Dias","year":"2011","unstructured":"Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424\u20131427 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"22867_CR42","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343\u20131346 (2016).","journal-title":"Science"},{"key":"22867_CR43","doi-asserted-by":"crossref","unstructured":"Bornholdt, Z. A. et al. Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. mBio 7, e02154-15 (2016).","DOI":"10.1128\/mBio.02154-15"},{"key":"22867_CR44","doi-asserted-by":"publisher","first-page":"17182","DOI":"10.1073\/pnas.1414164111","volume":"111","author":"CD Murin","year":"2014","unstructured":"Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl Acad. Sci. USA 111, 17182\u201317187 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22867_CR45","doi-asserted-by":"publisher","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","volume":"1","author":"J Pallesen","year":"2016","unstructured":"Pallesen, J. et al. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat. Microbiol. 1, 16128 (2016).","journal-title":"Nat. Microbiol."},{"key":"22867_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","volume":"164","author":"AI Flyak","year":"2016","unstructured":"Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164, 392\u2013405 (2016).","journal-title":"Cell"},{"key":"22867_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","volume":"52","author":"P Gilchuk","year":"2020","unstructured":"Gilchuk, P. et al. Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization. Immunity 52, 388\u2013403.e312 (2020).","journal-title":"Immunity"},{"key":"22867_CR48","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","volume":"174","author":"EO Saphire","year":"2018","unstructured":"Saphire, E. O. et al. Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell 174, 938\u2013952.e913 (2018).","journal-title":"Cell"},{"key":"22867_CR49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.coi.2010.02.012","volume":"22","author":"LM Walker","year":"2010","unstructured":"Walker, L. M. & Burton, D. R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22, 358\u2013366 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"22867_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12517","volume":"275","author":"BF Haynes","year":"2017","unstructured":"Haynes, B. F. & Mascola, J. R. The quest for an antibody-based HIV vaccine. Immunol. Rev. 275, 5\u201310 (2017).","journal-title":"Immunol. Rev."},{"key":"22867_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/imr.12481","volume":"275","author":"RW Sanders","year":"2017","unstructured":"Sanders, R. W. & Moore, J. P. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275, 161\u2013182 (2017).","journal-title":"Immunol. Rev."},{"key":"22867_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imr.12507","volume":"275","author":"AB Ward","year":"2017","unstructured":"Ward, A. B. & Wilson, I. A. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol. Rev. 275, 21\u201332 (2017).","journal-title":"Immunol. Rev."},{"key":"22867_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10409230802058320","volume":"43","author":"JM White","year":"2008","unstructured":"White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43, 189\u2013219 (2008).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"22867_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","volume":"479","author":"SC Harrison","year":"2015","unstructured":"Harrison, S. C. Viral membrane fusion. Virology 479, 498\u2013507 (2015).","journal-title":"Virology"},{"key":"22867_CR55","doi-asserted-by":"publisher","first-page":"aau6769","DOI":"10.1126\/sciadv.aau6769","volume":"4","author":"L He","year":"2018","unstructured":"He, L. et al. HIV-1 vaccine design through minimizing envelope metastability. Sci. Adv. 4, aau6769 (2018).","journal-title":"Sci. Adv."},{"key":"22867_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12040","volume":"7","author":"L Kong","year":"2016","unstructured":"Kong, L. et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat. Commun. 7, 12040 (2016).","journal-title":"Nat. Commun."},{"key":"22867_CR57","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1016\/j.celrep.2018.08.051","volume":"24","author":"Y Aldon","year":"2018","unstructured":"Aldon, Y. et al. Rational design of DNA-expressed stabilized native-like HIV-1 envelope trimers. Cell Rep. 24, 3324\u20133338.e3325 (2018).","journal-title":"Cell Rep."},{"key":"22867_CR58","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/COH.0000000000000549","volume":"14","author":"PJM Brouwer","year":"2019","unstructured":"Brouwer, P. J. M. & Sanders, R. W. Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. Curr. Opin. HIV AIDS 14, 302\u2013308 (2019).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"22867_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.coi.2019.03.003","volume":"59","author":"DW Kulp","year":"2019","unstructured":"Kulp, D. W. & Xu, Z. Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines. Curr. Opin. Immunol. 59, 49\u201356 (2019).","journal-title":"Curr. Opin. Immunol."},{"key":"22867_CR60","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1086\/520583","volume":"196","author":"KL Warfield","year":"2007","unstructured":"Warfield, K. L. et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196, S430\u2013S437 (2007).","journal-title":"J. Infect. Dis."},{"key":"22867_CR61","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","volume":"23","author":"DL Swenson","year":"2005","unstructured":"Swenson, D. L. et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23, 3033\u20133042 (2005).","journal-title":"Vaccine"},{"key":"22867_CR62","doi-asserted-by":"publisher","first-page":"15889","DOI":"10.1073\/pnas.2237038100","volume":"100","author":"KL Warfield","year":"2003","unstructured":"Warfield, K. L. et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl Acad. Sci. USA 100, 15889\u201315894 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22867_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev-micro-090817-062414","volume":"72","author":"H Feldmann","year":"2018","unstructured":"Feldmann, H., Feldmann, F. & Marzi, A. Ebola: Lessons on vaccine development. Annu. Rev. Microbiol. 72, 423\u2013446 (2018).","journal-title":"Annu. Rev. Microbiol."},{"key":"22867_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12041","volume":"7","author":"L He","year":"2016","unstructured":"He, L. et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat. Commun. 7, 12041 (2016).","journal-title":"Nat. Commun."},{"key":"22867_CR65","doi-asserted-by":"publisher","first-page":"eaaz6225","DOI":"10.1126\/sciadv.aaz6225","volume":"6","author":"LL He","year":"2020","unstructured":"He, L. L. et al. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci. Adv. 6, eaaz6225 (2020).","journal-title":"Sci. Adv."},{"key":"22867_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature18615","volume":"535","author":"YG Zhao","year":"2016","unstructured":"Zhao, Y. G. et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535, 169\u2013172 (2016).","journal-title":"Nature"},{"key":"22867_CR67","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1128\/JVI.03473-14","volume":"89","author":"P Pugach","year":"2015","unstructured":"Pugach, P. et al. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 89, 3380\u20133395 (2015).","journal-title":"J. Virol."},{"key":"22867_CR68","doi-asserted-by":"publisher","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).","journal-title":"PLoS Pathog."},{"key":"22867_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0210-4","volume":"12","author":"K Sliepen","year":"2015","unstructured":"Sliepen, K. et al. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology 12, 82 (2015).","journal-title":"Retrovirology"},{"key":"22867_CR70","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1126\/science.1245627","volume":"342","author":"D Lyumkis","year":"2013","unstructured":"Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484\u20131490 (2013).","journal-title":"Science"},{"key":"22867_CR71","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1126\/science.1245625","volume":"342","author":"J-P Julien","year":"2013","unstructured":"Julien, J.-P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477\u20131483 (2013).","journal-title":"Science"},{"key":"22867_CR72","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1021\/acs.jmedchem.8b01328","volume":"62","author":"F Shaikh","year":"2019","unstructured":"Shaikh, F. et al. Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library. J. Med. Chem. 62, 2928\u20132937 (2019).","journal-title":"J. Med. Chem."},{"key":"22867_CR73","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/acs.jmedchem.7b01249","volume":"61","author":"JS Ren","year":"2018","unstructured":"Ren, J. S., Zhao, Y. G., Fry, E. E. & Stuart, D. I. Target identification and mode of action of four chemically divergent drugs against ebolavirus infection. J. Med. Chem. 61, 724\u2013733 (2018).","journal-title":"J. Med. Chem."},{"key":"22867_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09732-7","volume":"10","author":"LB King","year":"2019","unstructured":"King, L. B. et al. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nat. Commun. 10, 1788 (2019).","journal-title":"Nat. Commun."},{"key":"22867_CR75","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/sj.emboj.7600219","volume":"23","author":"O Dolnik","year":"2004","unstructured":"Dolnik, O. et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 23, 2175\u20132184 (2004).","journal-title":"EMBO J."},{"key":"22867_CR76","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","volume":"73","author":"T Maruyama","year":"1999","unstructured":"Maruyama, T. et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73, 6024\u20136030 (1999).","journal-title":"J. Virol."},{"key":"22867_CR77","doi-asserted-by":"crossref","unstructured":"Janus, B. M. et al. Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop. Nat. Commun. 9, 3934 (2018).","DOI":"10.1038\/s41467-018-06113-4"},{"key":"22867_CR78","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nature04322","volume":"439","author":"HS Yin","year":"2006","unstructured":"Yin, H. S., Wen, X. L., Paterson, R. G., Lamb, R. A. & Jardetzky, T. S. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439, 38\u201344 (2006).","journal-title":"Nature"},{"key":"22867_CR79","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1021\/bi0024759","volume":"40","author":"J Liu","year":"2001","unstructured":"Liu, J., Shu, W., Fagan, M. B., Nunberg, J. H. & Lu, M. Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: Implications for membrane fusion. Biochemistry 40, 2797\u20132807 (2001).","journal-title":"Biochemistry"},{"key":"22867_CR80","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1073\/pnas.96.6.2662","volume":"96","author":"VN Malashkevich","year":"1999","unstructured":"Malashkevich, V. N. et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-\u00c5 resolution. Proc. Natl Acad. Sci. USA 96, 2662\u20132667 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22867_CR81","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1021\/bi300976m","volume":"51","author":"JF Koellhoffer","year":"2012","unstructured":"Koellhoffer, J. F. et al. Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Biochemistry 51, 7665\u20137675 (2012).","journal-title":"Biochemistry"},{"key":"22867_CR82","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1021\/bi3000353","volume":"51","author":"JS Harrison","year":"2012","unstructured":"Harrison, J. S., Koellhoffer, J. F., Chandran, K. & Lai, J. R. Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain \u03b1-helical bundle. Biochemistry 51, 2515\u20132525 (2012).","journal-title":"Biochemistry"},{"key":"22867_CR83","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/22221751.2020.1745093","volume":"9","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerg. Microbes Infect. 9, 775\u2013786 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"22867_CR84","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1016\/j.celrep.2020.03.025","volume":"30","author":"L Rutten","year":"2020","unstructured":"Rutten, L. et al. Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell Rep. 30, 4540\u20134550.e4543 (2020).","journal-title":"Cell Rep."},{"key":"22867_CR85","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"22867_CR86","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923\u2013928 (2017).","journal-title":"Science"},{"key":"22867_CR87","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay, A. et al. ROSETTA3: An object-oriented software suite for the simulation and design of macromolecles. Methods Enzymol. 487, 545\u2013574 (2011).","journal-title":"Methods Enzymol."},{"key":"22867_CR88","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"22867_CR89","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431.e1417 (2019).","journal-title":"Cell"},{"key":"22867_CR90","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1126\/science.aaf8818","volume":"353","author":"JB Bale","year":"2016","unstructured":"Bale, J. B. et al. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science 353, 389\u2013394 (2016).","journal-title":"Science"},{"key":"22867_CR91","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.4049\/jimmunol.162.11.6602","volume":"162","author":"CR Winstead","year":"1999","unstructured":"Winstead, C. R., Zhai, S. K., Sethupathi, P. & Knight, K. L. Antigen-induced somatic diversification of rabbit IgH genes: gene conversion and point mutation. J. Immunol. 162, 6602\u20136612 (1999).","journal-title":"J. Immunol."},{"key":"22867_CR92","doi-asserted-by":"publisher","first-page":"e00036","DOI":"10.1128\/mBio.00036-17","volume":"8","author":"CD Morris","year":"2017","unstructured":"Morris, C. D. et al. Differential antibody responses to conserved HIV-1 neutralizing epitopes in the context of multivalent scaffolds and native-like gp140 trimers. mBio 8, e00036\u201300017 (2017).","journal-title":"mBio"},{"key":"22867_CR93","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/14760584.2016.1187566","volume":"15","author":"KA Martins","year":"2016","unstructured":"Martins, K. A., Jahrling, P. B., Bavari, S. & Kuhn, J. H. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev. Vaccines 15, 1101\u20131112 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"22867_CR94","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","volume":"27","author":"P Rijal","year":"2019","unstructured":"Rijal, P. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172\u2013186.e177 (2019).","journal-title":"Cell Rep."},{"key":"22867_CR95","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635\u20131646 (2016).","journal-title":"N. Engl. J. Med."},{"key":"22867_CR96","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","volume":"27","author":"M Meyer","year":"2019","unstructured":"Meyer, M., Malherbe, D. C. & Bukreyev, A. Can Ebola virus vaccines have universal immune correlates of protection? Trends Microbiol. 27, 8\u201316 (2019).","journal-title":"Trends Microbiol."},{"key":"22867_CR97","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","volume":"12","author":"TUJ Bruun","year":"2018","unstructured":"Bruun, T. U. J., Andersson, A. M. C., Draper, S. J. & Howarth, M. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano 12, 8855\u20138866 (2018).","journal-title":"ACS Nano"},{"key":"22867_CR98","doi-asserted-by":"publisher","first-page":"E690","DOI":"10.1073\/pnas.1115485109","volume":"109","author":"B Zakeri","year":"2012","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl Acad. Sci. USA 109, E690\u2013E697 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"22867_CR99","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1107\/S1744309110038212","volume":"66","author":"M-A Elsliger","year":"2010","unstructured":"Elsliger, M.-A. et al. The JCSG high-throughput structural biology pipeline. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 66, 1137\u20131142 (2010).","journal-title":"Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun."},{"key":"22867_CR100","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"22867_CR101","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"22867_CR102","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1107\/S0907444903008126","volume":"59","author":"E Potterton","year":"2003","unstructured":"Potterton, E., Briggs, P., Turkenburg, M. & Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D. Biol. Crystallogr. 59, 1131\u20131137 (2003).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"22867_CR103","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1107\/S0907444909042589","volume":"66","author":"A Vagin","year":"2010","unstructured":"Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D. Biol. Crystallogr. 66, 22\u201325 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"22867_CR104","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"22867_CR105","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1107\/S0907444904023510","volume":"60","author":"AA Vagin","year":"2004","unstructured":"Vagin, A. A. et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D. Biol. Crystallogr. 60, 2184\u20132195 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"22867_CR106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"22867_CR107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","volume":"151","author":"C Suloway","year":"2005","unstructured":"Suloway, C. et al. Automated molecular microscopy: The new Leginon system. J. Struct. Biol. 151, 41\u201360 (2005).","journal-title":"J. Struct. Biol."},{"key":"22867_CR108","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"22867_CR109","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2016.10.014","volume":"167","author":"WE Diehl","year":"2016","unstructured":"Diehl, W. E. et al. Ebola virus glycoprotein with increased infectivity dominated the 2013\u20132016 epidemic. Cell 167, 1088\u20131098.e1086 (2016).","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1038\/s41467-022-34108-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22867-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:34:52Z","timestamp":1699011292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22867-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22867"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22867-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.22.262634","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-022-34108-9","URL":"https:\/\/doi.org\/10.1038\/s41467-022-34108-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2633"}}